Across TCGA pan-cancer cohorts, PRAMEF7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRAMEF7 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PRAMEF7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF7 expression acts as an unfavorable survival marker.

BRCA and SARC are the cancer types where PRAMEF7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.287	0.903	<.001	24	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PRAMEF7 tumor-vs-normal RNA expression · all PRAMEF7 data types